Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea · Delayed Price · Currency is KRW 1,343,000
-43,000 (-3.10%)
At close: Jun 26, 2026
Samsung Biologics Stock Forecast
Stock Price Forecast
According to 23 analysts polled by S&P Global, Samsung Biologics stock has a consensus rating of "Strong Buy" and an average price target of ₩2,096,122. The average 1-year stock price forecast is 56.08% higher than the current stock price, while the lowest is ₩1,650,000 (+22.86%) and the highest is ₩2,613,811 (+94.62%).
Price Target: ₩2,096,122 (+56.08%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Samsung Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 16 | 16 | 15 | 14 | 13 |
| Buy | 10 | 10 | 9 | 9 | 10 | 10 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 24 | 26 | 25 | 24 | 24 | 23 |
Financial Forecast
Revenue This Year
5.36T
from 4.56T
Increased by 17.70%
Revenue Next Year
6.26T
from 5.36T
Increased by 16.71%
EPS This Year
40.44K
from 26.63K
Increased by 51.89%
EPS Next Year
47.69K
from 40.44K
Increased by 17.93%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is KRW.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 5.7T | ||
| Avg | 5.4T | ||
| Low | 5.1T |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 24.1% | ||
| Avg | 17.7% | ||
| Low | 10.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 44,898.19 | ||
| Avg | 40,443.95 | ||
| Low | 36,398.53 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 68.6% | ||
| Avg | 51.9% | ||
| Low | 36.7% |